Dublin, Sept. 17, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/tvswrk/global_ischemic) has announced the addition of the "Global Ischemic Heart Disease (IHD)Drugs Market 2015-2019" report to their offering.
The global IHD drugs market to grow at a CAGR of 3.61% during 2014-2019.
The report covers the present scenario and the growth prospects of the global IHD drugs market for the period 2015-2019. To calculate the market size, we consider the revenue generated from the sales of various branded therapies and generics, along with the drugs used as off-label for the treatment of IHD.
The market has huge growth opportunities for vendors because of the growing population of individuals with IHD. To capture maximum market shares and expand the focus area, vendors are investing more on R&D.
According to the report, the high prevalence of chronic conditions such as hypertension, diabetes, and cholesterol levels are leading to an increase in cardiovascular diseases. The people with diabetes are three to four times more likely to develop CVDs than people without diabetes.
Further, the report states that the availability of effective surgical treatments and the use of catheter based interventions pose a challenge to the growth of market. The need for specific therapeutics at the later stages of the disease leads to the increased reliance on stents and surgeries.
IHD includes:
- Angina pectoris
- Myocardial infarction.
Key Vendors
- AstraZeneca
- Bayer
- Eli Lilly
- Novartis
- Pfizer
- Sanofi
Other Prominent Vendors
- Actelion
- Amgen
- Baxter
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi-Sankyo
- Eisai
- F.Hoffmann-La Roche
- Gilead Sciences
- GlaxoSmithKline
- Human Stem Cells Institute
- Janssen Pharmaceuticals
- Juventas Therapeutics
- Lacer
- Merck
- Nuo Therapeutics
- Ono Pharmaceutical
- Pharmahungary Group
- Resverlogix
- Takeda Pharmaceutical Company
- Taxus Cardium
- The Medicines Company
- United Therapeutics
For more information visit http://www.researchandmarkets.com/research/tvswrk/global_ischemic